LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
The latest regulatory, legal, compliance, and technology news for labs and pathology practices.
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
By Dan Scungio...
By Mike O’Brien...
By Dan Scungio...
Pass-through billing arrangements are those in which labs send a test specimen to an outside lab for testing and then bill the patient’s insurer for the test performed. Here’s a look at the potential liability risks and a strategy for managing them.